Skip to content
clinicaltrialshub.com
Clinical Trials Hub

Clinical trials, drug development and research news

Clinical Trials Hub: clinical trial and medical research news

The Mayo and Gonda buildings of Mayo Clinic in Rochester, Minnesota, home of MAJESTY lead investigator Fernando Fervenza
Drug Approvals

Rare kidney disease that leaks protein gets first approved drug

The FDA approved Gazyva for primary membranous nephropathy after the MAJESTY trial, where 37% of adults reached complete remission at two years, against 6% on tacrolimus. The US Food and Drug Administration approved Gazyva (obinutuzumab) on 13 November 2026 for adults with primary membranous nephropathy who are at risk of their disease getting worse.

· 13 November 2026

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.

Latest

Oncology

More →

Rare Diseases

More →

Cardiology

More →

Neurology

More →

Drug Approvals

More →

Industry & Regulation

More →